High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-24
DOI
10.1038/s41598-022-05208-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
- (2021) Sare Verstockt et al. INFLAMMATORY BOWEL DISEASES
- Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations
- (2020) Pascal Juillerat et al. DIGESTION
- Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe
- (2020) Alessandro Armuzzi et al. PLoS One
- Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab
- (2020) Lorenzo Bertani et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Positioning Therapies in the Management of Crohn’s Disease
- (2019) Nghia H. Nguyen et al. Clinical Gastroenterology and Hepatology
- Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)
- (2019) Sare Verstockt et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
- (2018) A. Barré et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
- (2017) L.C.S. De Vries et al. Journal of Crohns & Colitis
- Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease
- (2017) Nathaniel R West et al. NATURE MEDICINE
- Current and emerging therapeutic targets for IBD
- (2017) Markus F. Neurath Nature Reviews Gastroenterology & Hepatology
- Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology
- (2015) Heike M. Hermanns CYTOKINE & GROWTH FACTOR REVIEWS
- Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
- (2015) Brian Bressler et al. GASTROENTEROLOGY
- Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease
- (2014) D. T. Rubin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Youden Index and Optimal Cut-Point Estimated from Observations Affected by a Lower Limit of Detection
- (2008) Marcus D. Ruopp et al. BIOMETRICAL JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started